%0 Journal Article
%A Merz, Maximilian
%A Jauch, Anna
%A Hielscher, Thomas
%A Bochtler, Tilmann
%A Schönland, Stefan Olaf
%A Seckinger, Anja
%A Hose, Dirk
%A Bertsch, Uta
%A Neben, Kai
%A Raab, Marc Steffen
%A Hillengass, Jens
%A Salwender, Hans
%A Blau, Igor Wolfgang
%A Lindemann, Hans-Walter
%A Schmidt-Wolf, Ingo G H
%A Scheid, Christof
%A Haenel, Mathias
%A Weisel, Katja C
%A Goldschmidt, Hartmut
%T Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma.
%J Blood advances
%V 2
%N 1
%@ 2473-9537
%C Washington, DC
%I American Society of Hematology
%M DKFZ-2018-01908
%P 1 - 9
%D 2018
%X We investigated subclonal cytogenetic aberrations (CA) detected by interphase fluorescence in situ hybridization (iFISH) in patients with newly diagnosed multiple myeloma (MM) enrolled in the Haemato Oncology Foundation for Adults in the Netherlands (HOVON)-65/German-Speaking MM Group (GMMG)-HD4 phase 3 trial. Patients were either treated with 3 cycles of vincristine, Adriamycin, and dexamethasone or bortezomib, Adriamycin, and dexamethasone and then thalidomide or bortezomib maintenance after tandem autologous transplantation. Subclones were defined either by presence of different copy numbers of the same chromosome loci and/or CA present in at least 30
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:29344579
%2 pmc:PMC5761630
%R 10.1182/bloodadvances.2017013334
%U https://inrepo02.dkfz.de/record/141402